Background: Late gadolinium enhancement (LGE-) cardiovascular magnetic resonance (CMR) is well-validated for cardiac mass (C MASS ) tissue characterization to differentiate neoplasm (C NEO ) from thrombus (C THR ): Prognostic implications of C MASS subtypes among systemic cancer patients are unknown. Methods: C MASS + patients and controls (C MASS -) matched for cancer diagnosis and stage underwent a standardized CMR protocol, including LGE-CMR (IR-GRE) for tissue characterization and balanced steady state free precession cine-CMR (SSFP) for cardiac structure/function. C MASS subtypes (C NEO , C THR ) were respectively defined by presence or absence of enhancement on LGE-CMR; lesions were quantified for tissue properties (contrast-to-noise ratio (CNR); signal-to-noise ratio (SNR) and size. Clinical follow-up was performed to evaluate prognosis in relation to C MASS etiology. Results: The study population comprised 126 patients with systemic neoplasms referred for CMR, of whom 50% (n = 63) had C MASS + (C NEO = 32%, C THR = 18%). Cancer etiology differed between C NEO (sarcoma = 20%, lung = 18%) and C THR (lymphoma = 30%, GI = 26%); cardiac function (left ventricular ejection fraction: 63 ± 9 vs. 62 ± 10%; p = 0.51| right ventricular ejection fraction: 53 ± 9 vs. 54 ± 8%; p = 0.47) and geometric indices were similar (all p = NS). LGE-CMR tissue properties assessed by CNR (13.1 ± 13.0 vs. 1.6 ± 1.0; p < 0.001) and SNR (29.7 ± 20.4 vs. 15.0 ± 11.4, p = 0.003) were higher for C NEO , consistent with visually-assigned diagnostic categories. C THR were more likely to localize to the right atrium (78% vs. 25%, p < 0.001); nearly all (17/18) were associated with central catheters. Lesion size (17.3 ± 23.8 vs. 2. 0 ± 1.5 cm
; p < 0.001) was greater with C NEO vs. C THR , as was systemic disease burden (cancer-involved organs: 3.6 ± 2.0 vs. 2.3 ± 2.1; p = 0.02). Mortality during a median follow-up of 2.5 years was markedly higher among patients with C NEO compared to those with C THR (HR = 3.13 [CI 1.54-6.39], p = 0.002); prognosis was similar when patients were stratified by lesion size assessed via area (HR = 0.99 per cm 2 [CI 0.98-1.01], p = 0.40) or maximal diameter (HR = 0.98 per cm [CI 0.91-1.06], p = 0.61). C THR conferred similar mortality risk compared to cancer-matched controls without cardiac involvement (p = 0.64) whereas mortality associated with C NEO was slightly higher albeit non-significant (p = 0.12).
(Continued on next page) (Continued from previous page) Conclusions: Among a broad cancer cohort with cardiac masses, C NEO defined by LGE-CMR tissue characterization conferred markedly poorer prognosis than C THR , whereas anatomic assessment via cine-CMR did not stratify mortality risk. Both C NEO and C THR are associated with similar prognosis compared to C MASS -controls matched for cancer type and disease extent.
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Background
Patients with systemic cancer are at substantial risk for development of cardiac masses (C MASS ), including cardiac neoplasm (C NEO ) and thrombus (C THR ) [1] [2] [3] [4] [5] . Differentiation between C NEO and C THR impacts therapeutic decision-making, including use of anti-cancer therapies and anticoagulation. However, discrimination between the two based on anatomic appearance alone can be challenging, as C NEO and C THR can be similar in size and shape. Given the need to target therapeutic approaches and stratify prognosis in relation to C MASS etiology, accurate differentiation between C NEO and C THR is of substantial importance.
One approach to discriminate between neoplasm and thrombus stems from tissue properties relating to presence or absence of vascular supply. C NEO requires vascularity for tumorigenesis, whereas C THR can be intrinsically defined based on avascularity. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging enables C NEO to be differentiated from C THR based on vascular composition. Prior research by our group and others has validated LGE-CMR as a highly accurate test for thrombus among non-cancer cohorts, including post--myocardial infarction and heart failure patients in whom LGE-CMR evidenced left ventricular (LV) thrombus has been shown to correlate with histopathology findings, and yield incremental utility (compared to anatomic imaging) for stratification of thrombo-embolic events [6] [7] [8] [9] . More recently, we have employed LGE-CMR tissue characterization to identify C NEO among patients with advanced systemic cancer, among whom prognosis paralleled cancer etiology and systemic disease burden [3] . However, prior research to date has been limited to patient cohorts with either C NEO or C THR , thereby prohibiting comparison of risk factors and differential prognosis associated with each of these two conditions. This study employed LGE-CMR tissue characterization to assess C NEO and C THR among a broad cohort of at-risk patients with systemic cancer. Study aims were as follows: (1) identify cancer-associated risk factors predisposing to C NEO and C THR ; (2) compare anatomic location, function sequelae, and contrast-enhanced tissue properties of C NEO and C THR ; and (3) assess relative prognostic implications of C NEO and C THR compared to controls matched for cancer etiology and extra-cardiac disease burden.
Methods

Study population
The population included adults (≥18 years old) with systemic neoplasms with and without evidence of C MASS as identified by late gadolinium enhancement (LGE-) CMR: C MASS was defined as a discrete tissue prominence within either a cardiac chamber or pericardium, which demonstrated distinct enhancement pattern from surrounding myocardium. Patients with liquid tumors (i.e. leukemia) as well as primary cardiac malignancies were excluded. Established criteria [3, [7] [8] [9] were used to distinguish C MASS subtypes: (1) Neoplasm (C NEO ) was defined as C MASS with evidence of vascularity on LGE-CMR, defined by heterogeneous or diffuse contrast enhancement. (2) Thrombus (C THR ) was defined as C MASS without contrast enhancement. C MASS + patients (i.e. C NEO and C THR ) were each matched (1:1) with patients with no cardiac mass (C MASS -) on LGE-CMR but equivalent primary cancer etiology and disease stage. Figure 1 provides an overall schematic of the research protocol. In all patients, comprehensive clinical data were collected in a standardized manner, including cancer etiology, coronary heart disease risk factors, and anti-cancer therapies administered within 6 months of CMR. C MASS data (imaging and clinical assessment) was collected as part of an ongoing registry of patients undergoing clinically indicated CMR, for which initial results (limited to C NEO patients) have been partially reported [3] . CMR was performed between September 2012 and January 2017 at Memorial Sloan Kettering Cancer Center (New York, New York, USA). Mortality status after CMR was assessed via review of electronic medical records so as to test prognosis in relation to presence and pattern of C MASS .
This study entailed analysis of imaging and ancillary data acquired for primarily clinical purposes; no dedicated interventions (imaging or otherwise) were performed for exclusively research purposes. Ethics approval for this protocol was provided by the Memorial Sloan Kettering Cancer Center Institutional Review Board, which approved a waiver of informed consent for analysis of pre-existing clinical data.
CMR protocol
CMR was performed on commercial (1.5 T [89%], 3.0 T [11%]) scanners (General Electric Healthcare, Waukesha, Wisconsin, USA). Exams included cine-and LGE-CMR, both of which were obtained in contiguous LV short-axis (from mitral annulus through the apex) and long-axis (2, 3, 4 chamber) imaging orientations. Cine-CMR utilized a balanced steady-state free precession (bSSFP) pulse sequence.
LGE-CMR utilized an inversion recovery pulse sequence; images were acquired following gadolinium (0.2 mmol/kg) infusion. Conventional (inversion time [TI]~300 msec) and "long TI" (TI 600 msec) were used to discern C MASS vascularity concordant with prior methods applied and validated by our group [3] : Conventional TI LGE-CMR was acquired uniformly in all patients; additional breath holds required for supplemental long TI LGE-CMR were tolerated in 97% (61/63) of C MASS + patients (100% C THR , 95% C NEO ).
Image analysis C MASS
Whereas C THR was intrinsically defined based on uniform absence of contrast uptake, C NEO lesions were categorized based on two distinct enhancement patterns: Heterogeneous lesions manifested both discrete hyperand hypoenhancement within a single mass; diffuse lesions manifested diffuse enhancement throughout the entire mass. Figure 2 provides representative examples of C MASS enhancement patterns on LGE-CMR.
Quantitatively signal-to-noise (SNR) and contrast-tonoise (CNR) ratios on (long-TI) LGE-CMR were also used to assess enhancement patterns. Analyses were performed concordant with established methods previously applied by our group [3] . For patients with multiple lesions, the largest mass (based on cumulative LGE-CMR review) was used for quantitative image analysis.
C NEO and C THR were scored in a binary manner (present or absent), and localized based on chamber location (right atrium [RA], right ventricle [RV], left atrium [LA], LV) or pericardial involvement. Anatomic and functional properties of lesions were measured on cine-CMR, including lesion size (area, perimeter, and orthogonal linear dimensions), border irregularity (perimeter/shortest orthogonal diameter), valvular adherence/regurgitation, and ventricular outflow tract obstruction.
Cardiac chamber geometry
Cine-CMR was used to measure cardiac structure and function, as well as to identify pericardial and pleural effusions. LV and RV chamber volumes and ejection fraction (EF) were quantified based on planimetry of end-diastolic and end-systolic short axis slices. LV mass (including papillary muscles and trabeculae) was measured at end-diastole. LA and RA areas were measured during atrial end-diastole in 4-chamber orientation.
Mode of spread and prognostic assessment
Clinical documentation and extra-cardiac imaging (within 6 months of CMR) were reviewed to evaluate overall tumor burden. Extent of metastatic disease (outside of primary cancer organ) was evaluated in accordance with established methods based on number of major organ systems involved (central nervous system, Fig. 1 Study Design. Schematic of overall study design, inclusive of baseline LGE-CMR (for mass tissue characterization) and subsequent clinical follow-up (for all cause mortality). Note that for all C MASS + patients, etiology (C NEO vs. C THR ) was established based on presence or absence of enhancement on LGE-CMR head/neck, lung, pleura, liver, gastrointestinal, genitourinary, bones/soft tissue, thoracic and abdominal lymph nodes); a cumulative scoring system was used with each organ system assigned one point [10] [11] [12] . Electronic medical records were reviewed to assess all-cause mortality status. Time to event (death) was calculated in relation to CMR.
Statistical methods
Comparisons between groups with or without C MASS , as well as between C MASS subtypes (C NEO vs C THR ) were made using Student's t-test (expressed as mean ± standard deviation) for continuous variables, and Chi-square or Fishers exact tests for categorical variables: Paired testing (e.g. paired t-test or McNemar's test) were employed for matched case-control comparisons. The Kaplan-Meier method estimated the survival function. Cox proportional hazards model with a shared gamma frailty were used to compare mortality risk between groups adjusting for the matching. Receiver operating characteristics (ROC) analysis was used to evaluate overall diagnostic test performance of given imaging parameters (e.g. lesion size, SNR, CNR) for differentiation between LGE-CMR designated C NEO and C THR , and to derive cutoffs for maximal sensitivity and specificity. Statistical calculations were performed using SPSS 24.0 (SPSS Inc. [International Business Machines, Inc., Armonk, New York, USA]) and Stata 13.0 for Windows. Two-sided p < 0.05 was considered indicative of statistical significance.
Results
Population characteristics
The study population comprised 126 patients with systemic neoplasms undergoing CMR, including 63 with cardiac masses (C MASS ). Table 1 reports clinical and imaging characteristics of the population, including comparisons between C MASS affected patients and matched controls, as well as between affected patients within each C MASS subtype (C NEO , C THR ). As shown, C MASS + patients had a slightly higher burden of extracardiac disease as assessed based on number of canceraffected organ systems (p = 0.02), but were similar with respect to age, gender, as well as cardiac remodeling and functional indices (all p = NS). Cancer subtype was verified by pathology in all patients; 13% (n = 5) of patients with C NEO underwent tissue-based verification of mass etiology: Results demonstrated uniform concordance between biopsy and CMR-designation of C NEO based on mass-associated contrast-enhancement.
Regarding comparisons between C MASS subtypes, Table 1 demonstrates that C NEO and C THR differed with respect to cancer etiology: Among patients with C THR , lymphoma (30%) and gastrointestinal tumors (26%) were the most common underlying malignancies. Among patients with C NEO , sarcoma (20%) and lung (18%) were most common, although cancers not typically associated with cardiac involvement (e.g. endocrine, head and neck carcinomas) were also included in the study cohort. Whereas the majority of patients with C NEO (100%) and C THR (87%) had pre-existing stage IV cancer (irrespective of cardiac involvement), systemic disease burden -based on total number of non-cardiac organ systems involved -was higher among patients with C NEO vs. those with C THR (p = 0.02). Table 2 compares anatomic distribution and sequelae of C NEO and C THR . As shown, right-sided chamber involvement (i.e. RA or RV) occurred in the majority of patients with either condition, prevalence of which was similar between C NEO and C THR (p = 0.14). C THR more commonly localized to the RA (78%; p < 0.001 vs. C NEO ) -nearly all cases (17/18) of right atrial C THR were associated with central venous catheters inserted for chemotherapy administration. Whereas nearly half (43%) of patients with C NEO had RV involvement (p = 0.001 vs. C THR ), individual chamber location was highly variable. Regarding distribution, rates of multichamber involvement tended to be higher among C NEO affected patients (23% vs. 4%, p = 0.08). Despite increased cardiac disease burden, assessed based on extent of chamber involvement and primary lesion size, C NEO was rarely associated with functional impairment or localized effusions on CMR. For example, only 13% of C NEO cases were associated with outflow tract or valvular stenosis, and only 25% were associated with pericardial effusions (8/10 in context of pericardial metastases). Figure 3a compares SNR and CNR between visually scored C NEO and C THR . As shown, both quantitative indices were higher within C NEO vs. C THR (SNR 29.7 ± 20.4 vs. 15.0 ± 11.4 | CNR 13.1 ± 13.0 vs. 1.6 ± 1.0; both p < 0.01), consistent with increased contrast uptake due vascular supply. Regarding C NEO subtypes, data shown in Fig. 3b indicate that lesions with diffuse enhancement tended to have higher SNR than did those with heterogeneous enhancement, although this was not statistically significant (38.3±27.5 vs. 24.0 ±11.7; p = 0.08): Neoplasm with either enhancement pattern had higher SNR than did C THR (15.0 ± 11.4; both p < 0.05). CNR was higher among lesions with visually scored heterogeneous enhancement (18.3±14.3) compared to either diffusely enhancing C NEO (5.2±3.9; p < 0.001) or C THR (1.6±1.0; p < 0.001), consistent with interspersed regions of tissue vascularity (enhancement) and tissue necrosis (non-enhancement). Tissue characterization differences between cardiac masses were paralleled by differences in anatomic features. As shown in Table 3 , overall comparisons between C NEO and C THR demonstrated the former to typically be larger, whether assessed based on area or linear dimensions (both p < 0.05). However, further stratification demonstrated differences to vary based on C NEO pattern of enhancement: Neoplastic lesions with heterogeneous enhancement tended to be larger than those with diffuse enhancement, whether quantified by area (p < 0.001) or linear dimensions (p < 0.1). Of note, while all anatomic indices were larger for heterogeneously enhancing lesions compared to C THR , (p < 0.005), diffusely enhancing C NEO lesions and C THR were not significantly different in size (p > 0.05). Figure 4 illustrates ROC curves concerning overall performance of CNR, SNR, and lesion size (area, maximal length) for differentiation between C MASS subtypes (C NEO , C THR ). Table 4 reports diagnostic test variables calculated using cutoffs derived from corresponding ROC curves. As shown, AUC (0.88 [0.79-0.97]) and diagnostic accuracy (85%) were highest for CNR, consistent with use of contrastenhancement as the criterion for C NEO . 
Anatomic distribution and Sequelae
Tissue characterization
Clinical outcomes
Among patients with C NEO , 8% (n = 3) underwent resection, 43% (n = 17) had a change in chemotherapy regimen and 13% (n = 5) underwent targeted radiation of the heart and/or mediastinum within 6 months after CMR. Less than half of C NEO patients were treated with anticoagulation, as compared to nearly all patients with C THR (38% vs. 96%, p < 0.001). Regarding embolic events, pulmonary embolism was more common among patients with C MASS (18% vs. 6%, p = 0.12), as well as among patients with right sided C MASS + compared to controls (C MASS -) or C MASS + patients with isolated left sided involvement (24% vs. 6%, p = 0.004): Among C MASS subtypes, pulmonary embolism rates were similarly high among patients with C NEO (20%) and C THR (13%). Rates of cerebrovascular accident were identical between patients with and without C MASS (6% vs. 5%, p = 1.00), and did not differ when patients were further stratified by left sided C MASS location (10% vs. 5%, p = 0.31). Patient mortality was assessed following CMR to test the impact of C MASS related tissue properties on clinical prognosis. Median duration of post-CMR follow-up was 2.5 years (IQR 1.1-3.8) among survivors; median survival after imaging was 1 year. Figure 5 provides Kaplan Meier survival curves of C NEO and C THR affected patients, as well as controls (C MASS ) matched for primary cancer type and stage. As shown, mortality risk was similar between C THR affected patients and controls (hazard ratio [HR] = 0.82 [CI 0.35-1.89], p = 0.64). In contrast, C NEO affected patients tended towards slightly higher mortality compared to controls, although differences were non-significant (HR = 1.50 [CI 0.90-2.49], p = 0.12). Risk for death by 6 months post-CMR among C NEO and C THR patients compared to cancer-matched controls without cardiac involvement were (C NEO : 50% vs. 38% | C THR : 22% vs. 22%); corresponding risks at 1 year were proportionately higher (C NEO : 61% vs. 57% | C THR : 35% vs. 35%).
Comparisons between C NEO and C THR affected patients demonstrated prognosis to be markedly worse among the former (HR = 3.13 [CI 1.54-6.39], p = 0.002); mortality was approximately 2-fold higher among patients with C NEO at 6 months (50% vs. 22%) and at 1-year (61% vs. 35%) post-CMR. Of note, C NEO was associated with increased mortality risk, whereas lesion size -as assessed via area (HR = 0. 
Discussion
This is the largest study to date examining anatomic pattern, tissue properties, and differential prognostic implications of CMR-evidenced cardiac masses (C MASS +) among patients with systemic cancer. Key findings are as follows. First, among a broad cancer cohort for which C MASS + etiology was defined based on presence or absence of contrast enhancement on LGE-CMR, likelihood of C NEO paralleled extra-cardiac disease burden -as evidenced by higher total number of non-cardiac organ systems involved among patients with C NEO vs. C THR (p = 0.02). Second, whereas C THR was classified based on uniform absence of enhancement, two distinct C NEO patterns were identified -heterogeneous and diffuse enhancement. CNR was highest among lesions with heterogeneous enhancement (p < 0.001) -consistent with interspersed regions of tissue vascularity and tissue necrosis. C NEO lesions with heterogeneous enhancement were larger than C NEO lesions with diffuse enhancement, as well as C THR (both p < 0.05). Conversely, diffusely enhancing C NEO lesions and C THR were of similar size (p = NS Regarding the diagnostic approach employed in our study, it is important to recognize the concept that C NEO can be distinguished from C THR based on contrastenhancement is not modality specific: For example, Kirkpatrick et al. -studying a cohort in whom pathology and anticoagulation response were respectively used to verify C NEO and C THR , reported that contrast uptake on perfusion echocardiography was uniformly associated with malignant C NEO whereas hypo-enhancement was associated with C THR [13] . Given the established concept that C NEO manifests contrast-enhancement due to intrinsic vascular supply, and that vascularity is a key component for cellular proliferation/lesion growth, our finding that C NEO were generally larger than C THR is consistent with general concepts in tumor biology, for which lesion growth has been shown to correlate with vascular supply [14] [15] [16] . Our results also show that cancer-associated enhancement on LGE-CMR can vary in pattern, manifesting as diffuse or heterogeneous enhancement. The notion that heterogeneous enhancement on CMR is a marker of tissue necrosis has also been demonstrated via non-cardiac magnetic resonance imaging (MRI): Among patients with hepatic cell carcinoma, central hypo-enhancement on liver MRI has been shown to correspond to pathology-evidenced coagulation necrosis [17] . Regarding mechanism, in-vitro and ex-vivo studies have shown tumor necrosis to stem from mismatch between tumor growth and vascular supply, leading to cell death and tissue necrosis [18, 19] . It is possible that heterogeneous enhancing C NEO may be For both C NEO and C THR , controls were matched for primary cancer type and stage. Note higher mortality among patients with C NEO vs. C THR (p = 0.002); C THR conferred similar mortality risk compared to respective cancer-matched controls whereas mortality associated with C NEO was slightly higher albeit non-significant partially attributable to surface thrombosis, as can be superimposed on necrotic and/or hypercoagulable tissue. Whereas our study did not directly perform serial imaging to directly assess tumor growth or therapeutic response, our finding of increased lesion size among patients with heterogeneous compared to diffusely enhancing C NEO is consistent with the notion that heterogeneous enhancement stems from underlying differences in tumor growth.
Our current findings add to growing literature demonstrating C MASS + tissue characterization to provide diagnostic and prognostic utility among cancer and noncancer cohorts. Prior data from our group has shown an association between LV thrombus (defined by LGE-CMR) and risk for embolic events among heart failure cohorts [6, 7] . Similarly, multicenter clinical trial data has shown LGE-CMR evidenced LV thrombus to predict all cause mortality [20] . Among patients with advanced cancer, recent data from our group has shown C NEO to be associated with poor prognosis (44% 6-month mortality) [3] . However, this analysis was limited to patients with LGE-CMR defined C NEO , thereby precluding study of differential prognosis associated with presence or absence of lesion-associated contrast-enhancement. Our current study addresses this key knowledge gap -findings support incremental utility of tissue characterization via LGE-CMR (vs. anatomic assessment via techniques such as cine-CMR or echo) to guide therapeutic decision-making and prognostic risk stratification for cancer-patients with cardiac masses.
It is noteworthy that while mortality rates markedly differed between patients with C NEO and C THR , prognosis of each group was similar to that of cancer-affected controls (C MASS -) matched for disease etiology and extent of extra-cardiac disease. Regarding C THR , we speculate that this is attributable to the fact that this condition is treatable (via anticoagulation) and that the majority of thrombosis was limited to the right atrium and thus not exposed to high pressure, systemic circulatory conditions predisposing to life-threatening embolization. Consistent with this notion, our findings suggest that patients with C THR on LGE-CMR were near uniformly treated with anticoagulants (96%). Regarding C NEO , our finding of a numerically higher although nonsignificant mortality rates vs. controls (p = 0.12) suggests that the primary determinant of outcome relates to cancer etiology and burden of systemic disease, for which cardiac involvement is only one component similar to that of other organ systems.
Several limitations should be noted. First, our study population was derived from patients with C MASS referred for clinical CMR at a single tertiary care cancer center: C MASS affected cases and controls were specifically matched for cancer etiology and extent of extracardiac disease to test the additive impact of presence and type of C MASS on survival. In this context, it is important to recognize that mortality rates among controls may not reflect those of a general population of advanced cancer patients, but rather survival in a select group for which cancer etiology and stage were similar to that of affected (C MASS +) cases. Mortality estimates should also be interpreted keeping in mind that our study included patients at various times after their diagnoses and only evaluated patients who were healthy enough to undergo CMR. Second, this study used LGE-CMR to define C MASS type (i.e. neoplasm or thrombus) based on presence or absence of contrast uptake so as to test an established imaging approach well validated based on prior research by our group and others [3, [6] [7] [8] [9] 20] . Alternative imaging strategies such as perfusion and T1 mapping can also measure contrast-enhancement in a manner similar to LGE-CMR -these methods were not tested in our study, but hold potential for quantitative assessment of C MASS associated enhancement. Third, our estimates of diagnostic test performance (e.g. accuracy) for given imaging parameters (e.g. CNR, SNR) were assessed using cutoff values chosen from the same data and are likely optimistic. Finally, it should be noted that our study included a broad array of patients with different primary cancer diagnoses. Whereas C MASS + patients were matched (1:1) to C MASS -patients with equivalent cancer type and stage so as to test impact of presence and type of C MASS on prognosis, heterogeneity in cancer etiology is a potential confounding variable that could have impacted our results. Further larger studies in uniform cancer populations are needed to examine impact of C MASS tissue properties on cancer-associated outcomes.
Conclusions
Findings of this study demonstrate that among cancer patients with C MASS , presence or absence of LGE-CMR evidenced contrast-enhancement is a powerful prognostic indicator: C NEO as defined by LGE-CMR tissue characterization conferred markedly poorer prognosis than C THR , whereas anatomic assessment of lesion size via cine-CMR did not stratify mortality risk. Both C NEO and C THR are associated with similar prognosis compared to C MASS -controls matched for cancer type and disease extent. Future, multicenter research among patients with C NEO is warranted to test whether prognosis or therapeutic response varies based on pattern or extent of enhancement as measured by LGE-CMR or emerging CMR tissue characterization approaches. 
